首页> 外文期刊>Medicine. >Comparing efficacy of drug-coated balloon-only approach and stent approach in treating de novo coronary artery lesions: A meta-analysis of randomized controlled trials. A protocol for systematic review and meta-analysis
【24h】

Comparing efficacy of drug-coated balloon-only approach and stent approach in treating de novo coronary artery lesions: A meta-analysis of randomized controlled trials. A protocol for systematic review and meta-analysis

机译:比较药物涂层气球的疗效和近代冠状动脉病变治疗中的支架方法:随机对照试验的荟萃分析。系统审查和荟萃分析的协议

获取原文
       

摘要

Background: Drug-coated balloons (DCB) have been a novel alternative therapeutic strategy in de novo coronary artery diseases. However, the clinical feasibility of the DCB-only approach in treating small vessel disease remains controversial, while study aimed to assess the efficacy and safety of the DCB-only approach versus stent approaches in treating large vessel disease is limited. Methods: From February 2020 to May 2020, we will search Cochrane Library, PubMed, EMBASE, ScienceDirect, Scopus, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, and Chongqing VIP Database for eligible trials comparing DCB with drug-eluting stents for treatment of de novo lesions in both small vessel disease and large vessel disease. The primary endpoint is major adverse cardiac events (MACE); the secondary endpoints include in-lesion late lumen loss, binary restenosis, myocardial infarction, target lesion revascularization (TLR), mortality and target vessel thrombosis. Meta-analysis will be conducted using Review Manager software (V.5.3). Results: The results will be presented as risk ratios for dichotomous data, and weighted mean differences for continuous data. Conclusion: We will assess outcomes of the DCB-only approach in the treatment of de novo lesions compared with the stent approach.
机译:背景:药物涂层气球(DCB)是De Novo冠状动脉疾病的新型替代治疗策略。然而,在治疗小血管疾病方面的DCB的临床可行性仍然存在争议,而旨在评估DCB的疗效和安全性与治疗大容器病的效果和安全性有限。方法:从2020年2月到2020年5月,我们将搜索Cochrane图书馆,PubMed,Embase,SciErdirect,Scopus,中国生物医学文献数据库,中国国家知识基础设施(CNKI),Wanfang数据库和重庆VIP数据库,符合DCB与药物的符合DCB - 在小血管疾病和大型血管疾病中治疗De Novo病变的支架。主要终点是主要的不良心脏事件(MACE);次要终点包括病变后期内腔损失,二元再生,心肌梗塞,靶病变血运重建(TLR),死亡率和靶血管血栓形成。 Meta分析将使用Review Manager软件(V.5.3)进行。结果:结果将呈现为二分数据的风险比,以及对连续数据的加权平均差异。结论:与支架方法相比,我们将评估DCB的唯一方法的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号